Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada - PR Newswire
Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada PR Newswire
Semaglutide News
How Semaglutide Helped One Woman Reverse PMOS (Formerly PCOS) Symptoms After 14 Years - CU Anschutz newsroom
How Semaglutide Helped One Woman Reverse PMOS (Formerly PCOS) Symptoms After 14 Years CU Anschutz newsroom
GLP-1s Gain Ground in Liver Disease Care - Medscape
GLP-1s Gain Ground in Liver Disease Care Medscape
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada - Business Wire
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada Business Wire
Cheaper generic Ozempic is coming soon — but not for Americans. Here’s why. - NBC News
Cheaper generic Ozempic is coming soon — but not for Americans. Here’s why. NBC News
Novo Nordisk faces competition in Canada from Indian semaglutide copy - medwatch.com
Novo Nordisk faces competition in Canada from Indian semaglutide copy medwatch.com
What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile - Pharmacy Times
What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile Pharmacy Times
Oral semaglutide achieves 21.6% weight loss in early responders, doubles mobility gains - The Clinical Trial Vanguard
Oral semaglutide achieves 21.6% weight loss in early responders, doubles mobility gains The Clinical Trial Vanguard
Canada approves generic semaglutide from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent - drugdiscoverytrends.com
Canada approves generic semaglutide from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent drugdiscoverytrends.com
WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug - Health Policy Watch
WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug Health Policy Watch
Apotex Leapfrogs Dr Reddy’s With First Canadian Semaglutide Launch - Citeline News & Insights
Apotex Leapfrogs Dr Reddy’s With First Canadian Semaglutide Launch Citeline News & Insights
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial - PharmaTimes
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimes
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide - news-medical.net
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide news-medical.net
Ozempic (Semaglutide) Tablets Available Nationwide Starting May 4 - Medical Professionals Reference
Ozempic (Semaglutide) Tablets Available Nationwide Starting May 4 Medical Professionals Reference
6 Best Affordable Online Semaglutide Providers (2026) - Forbes
6 Best Affordable Online Semaglutide Providers (2026) Forbes
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes - Cureus
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes Cureus
Semaglutide offers weight-loss-independent benefits in MASH - Managed Healthcare Executive
Semaglutide offers weight-loss-independent benefits in MASH Managed Healthcare Executive
Ozempic delivers major weight loss in adults over 65, study finds - ScienceDaily
Ozempic delivers major weight loss in adults over 65, study finds ScienceDaily
Patients Over 65 With Obesity Respond Well to Semaglutide - Medscape
Patients Over 65 With Obesity Respond Well to Semaglutide Medscape
Oral semaglutide showed 21.6% weight loss in early responders, 77% mobility gains - The Clinical Trial Vanguard
Oral semaglutide showed 21.6% weight loss in early responders, 77% mobility gains The Clinical Trial Vanguard
FDA moves to remove GLP-1 medications from 503B Bulks List - Medical News Today
FDA moves to remove GLP-1 medications from 503B Bulks List Medical News Today
Wegovy vs Ozempic: Key Differences Between Semaglutide Drugs - Motley Rice
Wegovy vs Ozempic: Key Differences Between Semaglutide Drugs Motley Rice
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial - Nature
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial Nature
Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom - UT Southwestern Medical Center
Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom UT Southwestern Medical Center
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Dr Reddy's Laboratories (NYSE:RD - Benzinga
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Dr Reddy's Laboratories (NYSE:RD Benzinga
Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake - Nature
Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake Nature
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping - medRxiv
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping medRxiv
Semaglutide Improves Knee Replacements for Patients with Diabetes - Yale School of Medicine
Semaglutide Improves Knee Replacements for Patients with Diabetes Yale School of Medicine
Oral Semaglutide for Weight Loss: Key Facts About the Wegovy Pill - GoodRx
Oral Semaglutide for Weight Loss: Key Facts About the Wegovy Pill GoodRx
Semaglutide Erectile Dysfunction: Exploring Evidence-Based Supplements for Metabolic and Sexual Health Support - Portal CNJ
Semaglutide Erectile Dysfunction: Exploring Evidence-Based Supplements for Metabolic and Sexual Health Support Portal CNJ
Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats - Nature
Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats Nature
Semaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trial - Medical Xpress
Semaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trial Medical Xpress
GLP-1 plus therapy can reduce heavy drinking - National Institutes of Health (.gov)
GLP-1 plus therapy can reduce heavy drinking National Institutes of Health (.gov)
Semaglutide shows sustained weight loss benefits in older adults - news-medical.net
Semaglutide shows sustained weight loss benefits in older adults news-medical.net
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain - fda.gov
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain fda.gov
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial - Nature
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Nature
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison | International Journal of Obesity - Nature
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison | International Journal of Obesity Nature
New Data Show Semaglutide's Effects on Depression and Migraine - Drug Topics
New Data Show Semaglutide's Effects on Depression and Migraine Drug Topics
Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity - VCU Health
Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity VCU Health
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial - The Lancet
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial The Lancet